# US 2025/0375385 A1 · Capsule formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375385 A1
- Document ID: US20250375385A1
- Status: Published application
- Kind: A1
- Application number: 19/313,405
- Filed: 2025-08-28
- Published: 2025-12-11
- Earliest claimed: 2018-11-30
- Assignees: ChemoCentryx, Inc.
- Applicants: Chemocentryx, Inc.
- Inventors: Manhoman Reddy LELETI; Jay P. POWERS
- Web page: https://patentgrep.com/patent/US20250375385A1

## CPC

- A61K 9/4858: {Organic compounds}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.

## Claims

### Claim 1

A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form or in the form of a pharmaceutically acceptable salt
and a vehicle comprising
at least one non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) value of at least 10 and selected from the group consisting of a polyoxyethylene derivative of a fatty acid containing from about 8 to 22 carbon atoms, a polyoxyethylene hydrogenated castor oil or a polyoxyethylene castor oil, and
at least one water-soluble solubilizer having a melting point at or above 37° C. and selected from the group consisting of PEG-1000, PEG-1500, PEG-1540, PEG-2000, PEG-3000, PEG-3350, PEG-4000, PEG-6000, PEG-8000, PEG-10000, PEG-20000, poloxamer 188, poloxamer 237, poloxamer 338 and poloxamer 407.

### Claim 2 (depends on 1)

The solid solution capsule of claim 1, wherein the vehicle comprises about 97 to 99% by weight of the total fill weight of said solid solution capsule.

### Claim 3 (depends on 1)

The solid solution capsule of claim 1, wherein the vehicle comprises about 98% by weight of the total fill weight of said solid solution capsule.

### Claim 4 (depends on 1)

The solid solution capsule of claim 1, comprising about 1 to 3% of Compound 1 by weight of the total fill weight of said solid solution capsule.

### Claim 5 (depends on 1)

The solid solution capsule of claim 1, comprising about 2% of Compound 1 by weight of the total fill weight of said solid solution capsule.

### Claim 6 (depends on 1)

The solid solution capsule of claim 1, wherein the total weight of the vehicle comprises a 30:70 to 65:35 ratio of the at least one non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) value of at least 10 to the at least one water-soluble solubilizer having a melting temperature at or above 37° C.

### Claim 7 (depends on 1)

The solid solution capsule of claim 1, wherein the total weight of the vehicle comprises a 35:65 to 65:35 ratio of the at least one non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) value of at least 10 to the at least one water-soluble solubilizer having a melting temperature at or above 37° C.

### Claim 8 (depends on 1)

The solid solution capsule of claim 1, wherein the total weight of the vehicle comprises a 40:60 to 60:40 ratio of the at least one non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) value of at least 10 to the at least one water-soluble solubilizer having a melting temperature at or above 37° C.

### Claim 9 (depends on 1)

The solid solution capsule of claim 1, wherein the total weight of the vehicle comprises a 45:55 to 55:45 ratio of the at least one non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) value of at least 10 to the at least one water-soluble solubilizer having a melting temperature at or above 37° C.

### Claim 10 (depends on 1)

The solid solution capsule of claim 1, wherein the total weight of the vehicle comprises about a 50:50 ratio of the at least one non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) value of at least 10 to the at least one water-soluble solubilizer having a melting temperature at or above 37° C.

### Claim 11 (depends on 1)

The solid solution capsule of claim 1, wherein the at least one non-ionic surfactant having an HLB value of at least 10 comprises a polyoxyethylene derivative of ricinoleic acid.

### Claim 12 (depends on 1)

The solid solution capsule of claim 1, wherein the at least one non-ionic surfactant having an HLB value of at least 10 is macrogol-40-glycerol hydroxystearate or macrogolglycerol ricinoleate.

### Claim 13 (depends on 1)

The solid solution capsule of claim 1, wherein the at least one non-ionic surfactant having an HLB value of at least 10 is macrogol-40-glycerol hydroxystearate.

### Claim 14 (depends on 1)

The solid solution capsule of claim 1, wherein the at least one water-soluble solubilizer having a melting temperature at or above 37° C. is selected from the group consisting of PEG-1540, PEG-2000, PEG-3000, PEG-3350, PEG-4000, PEG-6000.

### Claim 15 (depends on 1)

The solid solution capsule of claim 1, wherein the at least one water-soluble solubilizer having a melting temperature at or above 37° C. is PEG-4000.

### Claim 16 (depends on 1)

The solid solution capsule of claim 1, wherein the at least one non-ionic surfactant having an HLB value of at least 10 is macrogol-40-glycerol hydroxystearate and the at least one water-soluble solubilizer having a melting temperature at or above 37° C. is PEG-4000.

### Claim 17 (depends on 1)

The solid solution capsule of claim 1, wherein the total fill weight of said solid solution capsule is from about 130 mg to 900 mg.

### Claim 18 (depends on 1)

The solid solution capsule of claim 1, wherein the total fill weight of said solid solution capsule is about 500 mg.

### Claim 19 (depends on 1)

The solid solution capsule of claim 1, wherein the at least one non-ionic surfactant having an HLB value of at least 10 is macrogol-40-glycerol hydroxystearate; the at least one water-soluble solubilizer having a melting temperature at or above 37° C. is PEG-4000; the vehicle comprises about 98% by weight of the total fill weight of said solid solution capsule; Compound 1 comprises about 2% by weight of the total fill weight of said solid solution capsule; and the total weight of the vehicle comprises about a 50:50 ratio of macrogol-40-glycerol hydroxystearate to PEG-4000.

### Claim 20 (depends on 1)

The solid solution capsule of claim 1, wherein the capsule size is #0.

### Claim 21 (depends on 1)

The solid solution capsule of claim 1, wherein the capsule is a hard capsule.

### Claim 22 (depends on 1)

A method for treating an individual suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors, comprising administering to the individual an effective amount of a solid solution capsule of claim 1.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disease or disorder is selected from the group consisting of anti-neutrophil cytoplasmic antibody associate (ANCA) vasculitis, C3 glomerulopathy, hidradenitis suppurativa, and lupus nephritis.

### Claim 24 (depends on 23)

The method of claim 23, wherein the disease or disorder is anti-neutrophil cytoplasmic antibody associate (ANCA) vasculitis.

### Claim 25 (depends on 6)

The solid solution capsule of claim 6, wherein the at least one non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) value of at least 10 is macrogol-40-glycerol hydroxystearate.

### Claim 26 (depends on 6)

The solid solution capsule of claim 6, wherein the at least one water-soluble solubilizer having a melting temperature at or above 37° C. is PEG-4000.

### Claim 27 (depends on 6)

The solid solution capsule of claim 6, wherein the at least one non-ionic surfactant having an HLB value of at least 10 is macrogol-40-glycerol hydroxystearate and the at least one water-soluble solubilizer having a melting temperature at or above 37° C. is PEG-4000.

### Claim 28 (depends on 7)

The solid solution capsule of claim 7, wherein the at least one non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) value of at least 10 is macrogol-40-glycerol hydroxystearate.

### Claim 29 (depends on 7)

The solid solution capsule of claim 7, wherein the at least one water-soluble solubilizer having a melting temperature at or above 37° C. is PEG-4000.

### Claim 30 (depends on 7)

The solid solution capsule of claim 7, wherein the at least one non-ionic surfactant having an HLB value of at least 10 is macrogol-40-glycerol hydroxystearate and the at least one water-soluble solubilizer having a melting temperature at or above 37° C. is PEG-4000.
